Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPA1 | P15085 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.35 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.35 |
| ▸ | MME | P08473 | 1/20 | 0.33 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14042757 | 1.00 | CPA1 (0.47) | CPA1ALDH1A1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL5245266 | 0.92 | CPA1 (0.51) | CPA1ALDH1A1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL12199163 | 0.86 | CPA1 (0.47) | CPA1ALDH1A1CYP2C19LMNATAS1R3 | |
| SCHEMBL1427009 | 0.85 | CPA1 (0.50) | CPA1ALDH1A1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL5163506 | 0.85 | CPA1 (0.50) | CPA1ALDH1A1CYP2C19LMNASMN1; SMN2 | |
| SCHEMBL13567330 | 0.80 | CPA1 (0.52) | CPA1 | |
| SCHEMBL1409156 | 0.80 | CPA1 (0.61) | CPA1ALDH1A1LMNAPOLB | |
| SCHEMBL4311206 | 0.78 | CPA1 (0.54) | CPA1ALDH1A1SMN1; SMN2POLB | |
| SCHEMBL18191192 | 0.78 | CPA1 (0.46) | CPA1ALDH1A1LMNASMN1; SMN2POLB | |
| SCHEMBL18191197 | 0.78 | CPA1 (0.46) | CPA1ALDH1A1LMNASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS (UK) LIMITED (GB) | 2011-08-04 | — | — | US | claimed |
| EP-2280930-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | Generics [UK] Limited (GB) | 2011-02-09 | — | — | EP | claimed |
| WO-2009147434-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | claimed |
| US-9745249-B2 | Method for the preparation of beta-substituted gamma-amino carboxylic acids | SIEGFRIED LTD. (CH) | 2017-08-29 | — | — | US | disclosed |
| US-9745249-B2 | Method for the preparation of beta-substituted gamma-amino carboxylic acids | SIEGFRIED LTD. (CH) | 2017-08-29 | — | — | US | disclosed |
| US-20170114003-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | SIEGFRIED LTD. (CH) | 2017-04-27 | — | — | US | disclosed |
| US-20170114003-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | SIEGFRIED LTD. (CH) | 2017-04-27 | — | — | US | disclosed |
| WO-2015189068-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | SIEGFRIED LTD. (CH) | 2015-12-17 | — | — | WO | disclosed |
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS (UK) LIMITED (GB) | 2011-08-04 | — | — | US | disclosed |
| EP-2280930-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | Generics [UK] Limited (GB) | 2011-02-09 | — | — | EP | disclosed |
| US-20090312560-A1 | PROCESSES FOR MAKING PREGABALIN AND INTERMEDIATES THEREFOR | SYNTHON BV (NL) | 2009-12-17 | — | — | US | disclosed |
| WO-2009149928-A1 | PROCESSES FOR MAKING PREGABALIN AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2009-12-17 | — | — | WO | disclosed |
| WO-2009147434-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| WO-2009147434-A1 | A NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GENERICS [UK] LIMITED (GB) | 2009-12-10 | — | — | WO | disclosed |
| US-7312335-B2 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
| US-7312335-B2 | Asymmetric Michael and Aldol additions using bifunctional cinchona-alkaloid-based catalysts | BRANDEIS UNIVERSITY (US) | 2007-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190393-A1 | NOVEL AND EFFICIENT METHOD FOR THE SYNTHESIS OF AN AMINO ACID | GLUL, GRIK5, GABRE | CPA1 2592/4885ALDH1A1 1509/4885CYP2C19 981/4885 |
| US-20170114003-A1 | METHOD FOR THE PREPARATION OF BETA-SUBSTITUTED GAMMA-AMINO CARBOXYLIC ACIDS | GLUL, GABRB2, GABRB1 | CPA1 2759/4885ALDH1A1 513/4885CYP2C19 306/4885 |
| US-20090312560-A1 | PROCESSES FOR MAKING PREGABALIN AND INTERMEDIATES THEREFOR | GABRB2, GABRB1, GABRB3 | CPA1 3552/4885ALDH1A1 510/4885CYP2C19 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.